Literature DB >> 11511564

Overexpression of activin A in stage IV colorectal cancer.

S Wildi1, J Kleeff, H Maruyama, C A Maurer, M W Büchler, M Korc.   

Abstract

BACKGROUND AND AIMS: Activins and inhibins are dimeric polypeptides that belong to the transforming growth factor beta (TGF-beta) superfamily and that bind to transmembrane receptors with serine/threonine kinase activity. The aim of this study was to characterise, in colon cancer cell lines and in normal and malignant human colon tissues, levels of expression of inhibin subunits that are involved in activin/inhibin dimer formation, and of the type I and II activin receptors (actRI and actRII).
METHODS: Expression of inhibin subunits and activin receptors was analysed by northern blot analysis. Inhibin betaA and activin receptor expression were also assessed by use of polymerase chain reaction (PCR). In addition, activin A/inhibin betaA localisation in human colon samples was assessed by immunohistochemistry and in situ hybridisation.
RESULTS: Inhibin betaA mRNA was expressed in CaCo2 cells but not in SW 837 or SW 1463 cells whereas inhibin betaB and inhibin alpha were below the level of detection. In contrast, all four activin receptors were present in the three cell lines. Colon cancers overexpressed inhibin betaA mRNA in comparison with normal colon, and this overexpression was greatest in stage IV tumours. ActRIb mRNA levels were slightly higher in the normal colon than in cancer tissues. By immunohistochemistry and in situ hybridisation, activin A and inhibin betaA mRNA were present in the mucosal epithelial cells in normal tissues from patients with stage I disease but were either absent or weakly present in normal tissues from patients with stage IV disease. Conversely, they were present at weak to moderate levels in stage I cancers but at high levels in stage IV cancers.
CONCLUSIONS: Our findings indicate that activin A is overexpressed in human colorectal tumours, especially in stage IV disease, raising the possibility that activin A may have a role in advanced colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11511564      PMCID: PMC1728425          DOI: 10.1136/gut.49.3.409

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  53 in total

1.  PCR MIMICS: competitive DNA fragments for use as internal standards in quantitative PCR.

Authors:  P D Siebert; J W Larrick
Journal:  Biotechniques       Date:  1993-02       Impact factor: 1.993

2.  Inhibition of vascular endothelial cell growth by activin-A.

Authors:  S A McCarthy; R Bicknell
Journal:  J Biol Chem       Date:  1993-11-05       Impact factor: 5.157

Review 3.  An update on the roles of inhibin, activin, and follistatin as local regulators of folliculogenesis.

Authors:  J K Findlay
Journal:  Biol Reprod       Date:  1993-01       Impact factor: 4.285

Review 4.  Role of transforming growth factor beta in colorectal cancer.

Authors:  H Lahm; N Odartchenko
Journal:  Growth Factors       Date:  1993       Impact factor: 2.511

5.  Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid.

Authors:  W Vale; J Rivier; J Vaughan; R McClintock; A Corrigan; W Woo; D Karr; J Spiess
Journal:  Nature       Date:  1986 Jun 19-25       Impact factor: 49.962

6.  Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity.

Authors:  P ten Dijke; H Ichijo; P Franzén; P Schulz; J Saras; H Toyoshima; C H Heldin; K Miyazono
Journal:  Oncogene       Date:  1993-10       Impact factor: 9.867

7.  Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha.

Authors:  M Korc; B Chandrasekar; Y Yamanaka; H Friess; M Buchier; H G Beger
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

8.  Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival.

Authors:  H Friess; Y Yamanaka; M Büchler; M Ebert; H G Beger; L I Gold; M Korc
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

9.  Activin A: an autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes.

Authors:  H Yasuda; T Mine; H Shibata; Y Eto; Y Hasegawa; T Takeuchi; S Asano; I Kojima
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

10.  Smad3 mutant mice develop metastatic colorectal cancer.

Authors:  Y Zhu; J A Richardson; L F Parada; J M Graff
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

View more
  31 in total

1.  Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma.

Authors:  Christopher W Seder; Wibisono Hartojo; Lin Lin; Amy L Silvers; Zhuwen Wang; Dafydd G Thomas; Thomas J Giordano; Guoan Chen; Andrew C Chang; Mark B Orringer; David G Beer
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

2.  Differentiation of single cell derived human mesenchymal stem cells into cells with a neuronal phenotype: RNA and microRNA expression profile.

Authors:  Francesca Crobu; Veronica Latini; Maria Franca Marongiu; Valeria Sogos; Franca Scintu; Susanna Porcu; Carla Casu; Manuela Badiali; Adele Sanna; Maria Francesca Manchinu; Maria Serafina Ristaldi
Journal:  Mol Biol Rep       Date:  2011-07-20       Impact factor: 2.316

Review 3.  Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer.

Authors:  Barbara Jung; Jonas J Staudacher; Daniel Beauchamp
Journal:  Gastroenterology       Date:  2016-10-20       Impact factor: 22.682

4.  Lymphatic metastasis-related TBL1XR1 enhances stemness and metastasis in gastric cancer stem-like cells by activating ERK1/2-SOX2 signaling.

Authors:  Jun Lu; Heejin Bang; Su Mi Kim; Soo-Jeong Cho; Hassan Ashktorab; Duane T Smoot; Chao-Hui Zheng; Sandra W Ryeom; Sam S Yoon; Changhwan Yoon; Jun Ho Lee
Journal:  Oncogene       Date:  2020-12-07       Impact factor: 9.867

5.  Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Authors:  Archana S Nagaraja; Robert L Dood; Guillermo Armaiz-Pena; Yu Kang; Sherry Y Wu; Julie K Allen; Nicholas B Jennings; Lingegowda S Mangala; Sunila Pradeep; Yasmin Lyons; Monika Haemmerle; Kshipra M Gharpure; Nouara C Sadaoui; Cristian Rodriguez-Aguayo; Cristina Ivan; Ying Wang; Keith Baggerly; Prahlad Ram; Gabriel Lopez-Berestein; Jinsong Liu; Samuel C Mok; Lorenzo Cohen; Susan K Lutgendorf; Steve W Cole; Anil K Sood
Journal:  JCI Insight       Date:  2017-08-17

6.  Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy.

Authors:  Yusuke Katayama; Takashi Oshima; Kentaro Sakamaki; Toru Aoyama; Tsutomu Sato; Katsuhiko Masudo; Manabu Shiozawa; Takaki Yoshikawa; Yasushi Rino; Toshio Imada; Munetaka Masuda
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

7.  TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles.

Authors:  Hanne Offenberg; Nils Brünner; Francisco Mansilla; F Orntoft Torben; Karin Birkenkamp-Demtroder
Journal:  Mol Oncol       Date:  2008-06-18       Impact factor: 6.603

8.  TGFβ and activin A in the tumor microenvironment in colorectal cancer.

Authors:  Jasmin Zessner-Spitzenberg; Alexandra L Thomas; Nancy L Krett; Barbara Jung
Journal:  Gene Rep       Date:  2019-09-12

Review 9.  Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.

Authors:  Jawed A Siddiqui; Ramesh Pothuraju; Maneesh Jain; Surinder K Batra; Mohd W Nasser
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-03-25       Impact factor: 10.680

10.  Functional roles of TGF-β1 in intestinal epithelial cells through Smad-dependent and non-Smad pathways.

Authors:  Yumi Yamada; Hirosato Mashima; Toshitaka Sakai; Tamotsu Matsuhashi; Mario Jin; Hirohide Ohnishi
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.